Insmed (INSM) COO Sells 25,000 Shares at ~$127–$128
Insmed Inc. insider sale disclosure: The company's Chief Operating Officer, Roger Adsett, reported selling a total of 25,000 shares of Insmed common stock on 08/19/2025 in two transactions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Insmed Inc. insider sale disclosure: The company's Chief Operating Officer, Roger Adsett, reported selling a total of 25,000 shares of Insmed common stock on 08/19/2025 in two transactions. The filings show 20,193 shares sold at a weighted-average price of $127.42 (range $127.00–$127.99) and 4,807 shares sold at a weighted-average price of $128.27 (range $128.00–$128.72). After these sales, the report lists beneficial ownership of 110,444 shares in one line and 105,637 shares in another line, each reported as direct ownership. The Form 4 was signed via power of attorney.
Positive
- Detailed trade disclosure with weighted-average prices and price ranges provided for both sale blocks
- Post-transaction direct ownership remains substantial (reported above 100,000 shares), indicating ongoing insider stake
Negative
- Insider sales of 25,000 shares could be viewed unfavorably by some investors despite being routine
- No explanation in the filing for the reason for the sales beyond the required transaction details
Insights
TL;DR: COO sold 25,000 shares in two blocks at ~$127–$128; ownership remains six-figure and is reported as direct.
The filing documents routine Section 16 reporting for officer stock sales rather than issuance or option exercise. The transaction is described as sales with specified price ranges and weighted-average prices; the reporting person retains substantial direct holdings after the trades. From a governance perspective, these are standard disclosures showing liquidity actions by an insider and use of a power of attorney signature.
TL;DR: Insider sold 25,000 shares at weighted averages of $127.42 and $128.27; remaining direct holdings exceed 100,000 shares.
The Form 4 provides explicit quantities and price ranges for sales executed on 08/19/2025, enabling verification of insider activity. The reported post-sale beneficial ownership figures indicate the insider still holds a material stake. There are no derivative transactions reported. The disclosure supplies sufficient granularity for trade size and price range inquiries.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 20,193 | $127.42 | $2.57M |
| Sale | Common Stock | 4,807 | $128.27 | $617K |
Footnotes (2)
- F1. This is the weighted average sales price representing 20,193 shares sold at prices ranging from $127.00 to $127.99 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F2. This is the weighted average sales price representing 4,807 shares sold at prices ranging from $128.00 to $128.72 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Insmed (INSM) insider Roger Adsett report on Form 4?
What was Roger Adsett's beneficial ownership after the reported sales?
Were any derivative securities reported in this Form 4 for INSM?
Who signed the Form 4 for Roger Adsett?
AI-generated analysis. How Rhea-AI works. Not financial advice.